KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bionano Genomics (BNGO) EBIAT (2017 - 2025)

Bionano Genomics (BNGO) has disclosed EBIAT for 9 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 60.58% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.4 million through Dec 2025, up 76.44% year-over-year, with the annual reading at -$26.4 million for FY2025, 76.44% up from the prior year.
  • EBIAT hit -$7.9 million in Q4 2025 for Bionano Genomics, up from -$8.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$3.1 million in Q1 2025 to a low of -$112.6 million in Q3 2023.
  • Historically, EBIAT has averaged -$28.8 million across 5 years, with a median of -$26.5 million in 2021.
  • Biggest five-year swings in EBIAT: tumbled 253.88% in 2023 and later skyrocketed 90.13% in 2025.
  • Year by year, EBIAT stood at -$22.9 million in 2021, then plummeted by 68.53% to -$38.7 million in 2022, then fell by 13.48% to -$43.9 million in 2023, then skyrocketed by 54.15% to -$20.1 million in 2024, then soared by 60.58% to -$7.9 million in 2025.
  • Business Quant data shows EBIAT for BNGO at -$7.9 million in Q4 2025, -$8.5 million in Q3 2025, and -$6.9 million in Q2 2025.